10:17 AM
 | 
May 05, 2019
 |  BC Extra  |  Clinical News

Cytokinetics looks beyond reldesemtiv miss in ALS

Editor's Note: This article was updated on May 06, 2019 at 1:36 PM PDT

Cytokinetics signaled its interest in continuing reldesemtiv’s development for ALS even as the candidate failed to meet the primary and secondary endpoints in the Phase II FORTITUDE-ALS trial to treat amyotrophic lateral sclerosis.

"We went into this trial sober to the reality that if these data aren't compelling, we might have to reevaluate our commitment to discovering and developing fast skeletal troponin activators for neuromuscular conditions," Robert Blum, president and CEO of Cytokinetics Inc. (NASDAQ:CYTK), told BioCentury. "We were objective about what we needed to see in this trial, and we saw what we needed to see."

On the...

Read the full 478 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >